Key result
Early dabigatran linked to ~32% lower major bleeding vs. VKA after acute stroke.
Why the study?
The optimal timing of initiating or resuming anticoagulation after acute ischemic stroke or transient ischemic attack in patients with atrial fibrillation is debated.
Does early (<= 7 days) or late (> 7 days) initiation of dabigatran reduce the risk of major hemorrhagic events within 3 months compared with vitamin K antagonists in patients with atrial fibrillation and recent acute ischemic stroke or TIA?
Cohort (n=3,312)
Yes
Does early (<= 7 days) or late (> 7 days) initiation of dabigatran reduce the risk of major hemorrhagic events within 3 months compared with vitamin K antagonists in patients with atrial fibrillation and recent acute ischemic stroke or TIA?
In real-world clinical practice, early (<=7 days) initiation of dabigatran after acute ischemic stroke or TIA in patients with atrial fibrillation showed numerically lower rates of major and intracranial hemorrhage than VKA without an increase in ischemic events, though low event counts limited statistical precision.
Answers are grounded in this paper and cite their sources.
Early dabigatran may lower major hemorrhage risk versus VKA post-stroke; leaves open optimal timing pending randomized confirmation.
BACKGROUND: The optimal timing of initiating or resuming anticoagulation after acute ischemic stroke (AIS) or transient ischemic attack (TIA) in patients with atrial fibrillation (AF) is debated. Dabigatran, a non-vitamin K oral anticoagulant (NOAC), has shown superiority against vitamin K antagonists (VKA) regarding hemorrhagic complications. AIMS: In this registry study, we investigated the initiation of dabigatran in the early phase after AIS or TIA. METHODS: PRODAST (Prospective Record of the Use of Dabigatran in Patients with Acute Stroke or TIA) is a prospective, multicenter, observational, post-authorization safety study. We recruited 10,039 patients at 86 German stroke units between July 2015 and November 2020. A total of 3,312 patients were treated with dabigatran or VKA and were eligible for the analysis that investigates risks for major hemorrhagic events within 3 months after early (⩽ 7 days) or late (> 7 days) initiation of dabigatran or VKA initiated at any time. Further endpoints were recurrent stroke, ischemic stroke, TIA, systemic embolism, myocardial infarction, death, and a composite endpoint of stroke, systemic embolism, life-threatening bleeding and death. RESULTS: Major bleeding event rates per 10,000 treatment days ranged from 1.9 for late administered dabigatran to 4.9 for VKA. Early or late initiation of dabigatran was associated with a lower hazard for major hemorrhages as compared to VKA use. The difference was pronounced for intracranial hemorrhages with an adjusted hazard ratio (HR) of 0.47 (95% confidence interval (CI): 0.10-2.21) for early dabigatran use versus VKA use and an adjusted HR of 0.09 (95% CI: 0.00-13.11) for late dabigatran use versus VKA use. No differences were found between early initiation of dabigatran versus VKA use regarding ischemic endpoints. CONCLUSIONS: The early application of dabigatran appears to be safer than VKA administered at any time point with regards to the risk of hemorrhagic complications and in particular for intracranial hemorrhage. This result, however, must be interpreted with caution in view of the low precision of the estimate.
No takes yet. Share an insight, caveat, or question.
Große et al. (2023) conducted a cohort in Acute ischemic stroke or transient ischemic attack with non-valvular atrial fibrillation (n=3,312). Early (<= 7 days) or late (> 7 days) initiation of dabigatran vs. Vitamin K antagonist (VKA) initiated at any time was evaluated on Major bleeding event within 3 months following the index event (early dabigatran vs VKA) (HR 0.68, 95% CI 0.32-1.47). Early initiation of dabigatran (<=7 days) after acute ischemic stroke or TIA was associated with a lower rate of major hemorrhage compared to VKA, though with low precision.
Synapse has enriched 10 related papers. Consider them for comparative context: